Core Viewpoint - The potential rescheduling of marijuana under the Controlled Substances Act in the U.S. could enhance legal clarity for patients traveling from Colombia with prescribed medical cannabis and may impact international trade and policy for compliant pharmaceutical suppliers [1]. Group 1: Legal Implications - The ongoing U.S. federal process to reschedule marijuana may lead to improved legal clarity for medical cannabis patients [1]. - Changes in the legal status of marijuana could affect the compliance requirements for pharmaceutical suppliers operating in the medical cannabis sector [1]. Group 2: International Trade - The rescheduling of marijuana could have significant implications for international trade, particularly for countries like Colombia that are involved in the medical cannabis industry [1]. - Colombian medical cannabis operators, such as Sannabis S.A.S., may benefit from clearer regulations that facilitate cross-border transactions [1].